Imugene toasts future after formative year
Tuesday, 16 September, 2003
Despite a decrease in revenues and an increase in net loss to AUD$1.3 million, veterinary biotechnology company Imugene (ASX:IMU) has come a long way in its first year as a biotechnology company, according to chairman Graham Dowland, who said it was a "tremendous formative year."
During the course of the year, the company acquired two animal health operations -- 100 per cent owned VectoGen and Paragen, which it owns in partnership with Murdoch University.
But the key defining moment for the company financially has been licence agreements for four of the company's products with two of the major multinational animal health groups, Merial and Intervet, providing revenues of $538,444.
"We're delighted we have some projects of real value," Dowland said.
Imugene ended the year with cash reserves of $2.6 million, which Dowland said would last 12 to 18 months. "In that time we will take projects several steps along the value chain," he said.
According to Dowland, Imugene has a busy year ahead, with more trials due to begin in October, and preparation for regulatory approval through the OGTR underway. In addition, the company is continuing to refine its technology.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
